Keep recycling going: new approaches to reduce LDL-C
Abstract
Hypercholesterolemia represents a leading cause in the development of atherosclerotic plaques, increasing the risk for ACVS. It actually counts as a major cause of cardiovascular disease etiopathogenesis. The causes of hypercholesterolemia are multifactorial, spanning from genetic constitution, age, sex, to sedentary lifestyle and diets rich in sugars and lipids. Although dietary restriction in saturated fats, increased exercise, and other modification in lifestyle represent a first-line approach to treat very initial stages in hypercholesterolemia, most patients will require the addition of pharmacological agents. Pharmacological approaches include inhibition of cholesterol synthesis, decreased fat absorption from the GI tract, and increased degradation of FA. These strategies present a series of side effects, low therapeutic efficiency in some patients, and reduced tolerability. One of the major goals in treatment for hypercholesterolemia is to decrease the levels of low density lipoproteins (LDL), while maintaining those of high density lipoproteins (HDL). LDL particles contain about 80% of lipids, most of it cholesterol and cholesteryl esters, and 20% of the ApoB-100 protein. LDL carries cholesterol to the tissues, to be incorporated to biological membranes, or to be transformed to steroids. Excess of LDL translates into increased levels of circulating cholesterol particles and accumulation in certain tissues, especially vascular tissue, initiating a fatty streak, which m…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The lack of significant improvements in physiological outcomes can be attributable to multiple factors beyond medication adherence, such as prescriber dosing, diet, and physical activity.
“This can be attributable to multiple factors beyond medication adherence, such as prescriber dosing, diet, and physical activity.67,68”
From Interventions to improve adherence to lipid-lowering drugs: a systematic review and meta-analysis (2025) · cites this paper as [68]
Cites
A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins
Goldstein, J. L., & Brown, M. S. (2015) · Cell · doi:10.1016/j.cell.2015.01.036 · Cited by 1,233 · see citing works
A highly durable RNAi therapeutic inhibitor of PCSK9
Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609243 · Cited by 768 · see citing works
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Blom, D. J., Hala, T., Bolognese, M., Lillestol, M. J., Toth, P. D., Burgess, L., Ceska, R., Roth, E., Koren, M. J., Ballantyne, C. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316222 · Cited by 720 · see citing works
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., Lisbon, E., Gutierrez, M., Webb, C., Wu, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105803 · Cited by 664 · see citing works
The Evolving Future of PCSK9 Inhibitors
Rosenson, R. S., Hegele, R. A., Fazio, S., & Cannon, C. P. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.054 · Cited by 264 · see citing works
Landmesser, U., Chapman, M. J., Stock, J. K., Amarenco, P., Belch, J. J. F., Borén, J., Farnier, M., Ference, B. A., Gielen, S., Graham, I., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx549 · Cited by 200 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Interventions to improve adherence to lipid-lowering drugs: a systematic review and meta-analysis
Yow, D. K. W., Ang, W. J., Yap, H. J., Ito, S., Liu, J., Ko, J., Tan, D. S.-Y., Lorenzatti, A., & Ang, C.-S. (2025) · eClinicalMedicine · doi:10.1016/j.eclinm.2025.103270 · Cited by 5 · see citing works
- Authors
- Klein-Szanto, A. J. P., & Bassi, D. E.
- Affiliations
- Fox Chase Cancer Center (US)
- Corresponding author
- Bassi, Daniel E.
- ORCID
- Bassi, Daniel E.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 164
- Pages
- 336-341
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W2932251388
- Cited by
- 46
- References
- 6
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 3 · 2023: 6 · 2022: 11 · 2021: 11 · 2020: 9
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- hypercholesterolemia, LDL cholesterol lowering, LDL receptor, LDL clearance, atherosclerosis, cardiovascular disease, PCSK9 inhibitors
- MeSH terms
- Animals, Anticholesteremic Agents, Humans, Hypercholesterolemia, Cholesterol, LDL, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review